Charles River Laboratories International, Inc. (NYSE:CRL) Insider Sells $643,364.10 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) insider Davide Molho sold 5,982 shares of Charles River Laboratories International stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the completion of the sale, the insider now directly owns 22,714 shares in the company, valued at approximately $2,442,890.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Davide Molho also recently made the following trade(s):

  • On Thursday, June 22nd, Davide Molho sold 10,948 shares of Charles River Laboratories International stock. The stock was sold at an average price of $100.00, for a total value of $1,094,800.00.

Shares of Charles River Laboratories International, Inc. (CRL) opened at 106.02 on Friday. The company has a market cap of $5.05 billion, a PE ratio of 27.94 and a beta of 0.99. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $109.59. The company has a 50 day moving average of $103.01 and a 200 day moving average of $95.28.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.20 earnings per share. On average, analysts expect that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

WARNING: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://ledgergazette.com/2017/09/17/charles-river-laboratories-international-inc-crl-insider-sells-643364-10-in-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in shares of Charles River Laboratories International by 12,573.1% during the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after acquiring an additional 3,815,298 shares during the last quarter. FMR LLC boosted its position in shares of Charles River Laboratories International by 39.7% during the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock worth $223,806,000 after acquiring an additional 707,612 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Charles River Laboratories International during the second quarter worth $65,915,000. Ariel Investments LLC boosted its position in shares of Charles River Laboratories International by 30.7% during the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock worth $185,335,000 after acquiring an additional 483,564 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of Charles River Laboratories International during the first quarter worth $39,355,000. Institutional investors and hedge funds own 95.82% of the company’s stock.

A number of equities analysts recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a report on Friday, June 30th. Citigroup Inc. restated a “neutral” rating and set a $104.00 price objective (up previously from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. Barclays PLC reiterated a “hold” rating and issued a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $98.55.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply